Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|May 1, 2008
- Volume 0 0
recruitment/RESOURCES
Advertisement
Articles in this issue
over 18 years ago
advertiserINDEXover 18 years ago
productHOTLINEover 18 years ago
Motion Sickness: Calming the Waves of Upsetover 18 years ago
pharmacy Pet Peevesover 18 years ago
canyouREADtheseRxs?over 18 years ago
Case Studiesover 18 years ago
DIABETESWATCHover 18 years ago
CHOLESTEROLWATCHover 18 years ago
compoundingHOTLINEover 18 years ago
ARTHRITISWATCHAdvertisement
Related to this article
Investigational anti-amyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Why 5 Injectable Drugs Have Been in Shortage for More Than a Decade
4
CKD Prevalence Unmoved Despite Billions in Virtual Care
5